Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter Extension Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-sponsored Phase I or Phase II Cancer Study

NCT00959647 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00959647
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00959647 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter Extension Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-sponsored Phase I or Phase II Cancer Study
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 3, 2009
Completion date
January 9, 2014
Enrollment
19 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

basal cell carcinoma, metastatic colorectal cancer, ovarian cancer